| Yondelis (trabectedin) / PharmaMar, J&J |
2016-005029-36: Vergleich der Lebensqualität bei Patientinnen mit platinsensitivem wiederkehrenden Eierstock-, Eileiter- und Bachfellkrebs bei der Behandlung mit Trabectedin / PLD oder einer platinbasierten Standardtherapie - eine Kooperation der NOGGO und BNGO |
|
|
| Ongoing | 4 | 206 | Europe | Trabectedin, Pegylated liposomal Doxorubicin, Carboplatin, Gemzitabin, Placlitaxel, L01XA02, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, Yondelis 1 mg powder for solution for infusion, Caelyx, Carboplatin, Gemcitabin, Paclitaxel | NOGGO e.V., PharmaMar, S.A. | Ovarian Cancer, cancer of the ovaries, Diseases [C] - Cancer [C04] | | | | |
COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
|
|
| Completed | 4 | 89 | Europe | Trabectidin (Yondelis) | North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar | Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma | 08/23 | 08/23 | | |
NCT00707109: Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 1200 | US | trabectedin, Yondelis | University of Medicine and Dentistry New Jersey, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Sarcoma | 12/09 | | | |
2020-005858-21: tTF-NGR Randomized Study - STS tTF-NGR randomisierte Studie - STS |
|
|
| Not yet recruiting | 3 | 126 | Europe | tTF-NGR, Yondelis, ET-743, Solution for infusion in pre-filled syringe, Powder for concentrate for solution for infusion, Yondelis | Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel, ANTUREC Pharmaceuticals GmbH | Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)., Patients with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs., Diseases [C] - Cancer [C04] | | | | |
MANTRA, NCT04979442: Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma |
|
|
| Terminated | 3 | 175 | Europe, Canada, US, RoW | RAIN-32, Milademetan, Trabectedin, Yondelis | Rain Oncology Inc | Dedifferentiated Liposarcoma | 10/23 | 10/23 | | |
2021-001394-23: Clinical study comparing Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma |
|
|
| Not yet recruiting | 3 | 160 | Europe | Milademetan, Trabectedin, DS-3032b, Capsule, Powder for concentrate for solution for infusion | Rain Therapeutics, Inc., Rain Oncology Inc., Rain Therapeuthic Inc, RAIN Therapeutics Inc. | Dedifferentiated liposarcoma, Liposarcoma, Diseases [C] - Cancer [C04] | | | | |
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas |
|
|
| Recruiting | 3 | 333 | US | INT230-6, Eribulin, Trabectedin, Pazopanib | Intensity Therapeutics, Inc., Premier Research Group plc | Sarcoma,Soft Tissue | 12/27 | 12/28 | | |
2017-001755-31: Study to Compare a Treatment with Trabectedin and Olaparib to Physician’s Choice in Subjects with Previously Treated Solid Tumors Having a Special lack of Cellular Repair Mechanism Studie zu einer Behandlung mit Trabectedin und Olaparib im Vergleich zu Standardbehandlung nach ärztlichem Ermessen bei Patienten mit soliden Tumoren, die eine gestörte Zellreparatur haben. |
|
|
| Not yet recruiting | 2 | 108 | Europe | Trabectedin, Olaparib, ET-743, Powder for concentrate for solution for infusion, Film-coated tablet, Yondelis | Ruprecht-Karls-Universität Heidelberg, Medical Faculty, DKFZ Heidelberg, AstraZeneca GmbH, Pharma Mar S.A. | Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Patienten mit lokal fortgeschrittenen bzw. metastasierten soliden Organtumoren bei molekulargenetisch nachgewiesenen Störungen im DNA-Reparaturweg, Previously Treated Advanced Tumors Fortgeschrittene Krebserkrankung, die bereits behandelt wurde, Diseases [C] - Cancer [C04] | | | | |
2018-000230-35: combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugs studio di trabectedina e olaparib nei tumori dell'ovaio delle tube di falloppio e dei primitivi del peritoneo in stadio avanzato in cui i trattamenti standard a base di platino non hanno più effetto. |
|
|
| Ongoing | 2 | 66 | Europe | yondelis, olaparib, [ET-743], [AZD-2281], Powder for solution for injection, Tablet, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO | FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS, AstraZeneca | platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum Carcinoma Ovarico, delle tube di Falloppio e dei primitivi del peritoneo platino-resistente, ovarian cancer, fallopian tubes cancer or primary of peritoneum no longer sensitive to standard platinum drugs tumore delle ovaie, delle tube e dei primtivi del peritoneo non più trattabile con i trattamenti standard a base di platino, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c |
|
|
| Not yet recruiting | 2 | 100 | Europe | Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML | ITALIAN SARCOMA GROUP, Pharmamar | metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-001083-38: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas |
|
|
| Not yet recruiting | 2 | 92 | Europe | Nivolumab, Trabectedin, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Opdivo®, Yondelis | Universitätsmedizin Greifswald, Bristol-Myers Squibb GmbH und Co. KG, Pharma Mar, S.A. | metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, metastatic or inoperable soft tissue sarcoma metastasiertes oder inoperables Weichteilsarkom, Diseases [C] - Cancer [C04] | | | | |
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma |
|
|
| Active, not recruiting | 2 | 29 | US | Olaparib, Trabectedin | University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca | Sarcoma, Sarcoma Metastatic | 01/23 | 01/25 | | |
| Completed | 2 | 102 | Europe | Olaparib, Physician's choice, Trabectedin | National Center for Tumor Diseases, Heidelberg, AstraZeneca, PharmaMar, German Cancer Research Center | Cancers With DNA Repair-Deficiency | 12/23 | 12/23 | | |
| Recruiting | 2 | 100 | Europe | Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort | Italian Sarcoma Group, PharmaMar | Leiomyosarcoma of Ovary, Soft Tissue Sarcoma | 06/24 | 09/24 | | |
| Recruiting | 2 | 16 | Europe | Trabectedin | Italian Sarcoma Group, PharmaMar | Mesenchymal Chondrosarcoma | 09/24 | 12/24 | | |
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour |
|
|
| Not yet recruiting | 2 | 198 | Europe | Doxorubicin, Trabectedin, Yondelis | UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole | Leiomyosarcoma Uterus | 12/29 | 12/30 | | |
| Active, not recruiting | 2 | 126 | Europe | Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm | Italian Sarcoma Group, PharmaMar, AstraZeneca | Advanced Soft Tissue Sarcoma | 02/25 | 02/25 | | |
2014-001549-26: Trial that evaluates the combination treatment of Trabectedin and Radiotherapy in Soft Tissue Sarcoma patients. Ensayo clínico que evalúa la combinación de Trabectedina y Radioterapia para el tratamiento de pacientes con sarcoma de tejidos blandas. |
|
|
| Ongoing | 1/2 | 148 | Europe | trabectedina, [trabectedina], Powder for concentrate for solution for infusion, YONDELIS 1 mg powder for concentrate for solution for infusion | GEIS, GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS, PharmaMar, Pharmamar | Soft Tissue Sarcoma Sarcoma de tejidos blandos, Soft Tissue Sarcoma Sarcoma de tejidos blandos, Diseases [C] - Cancer [C04] | | | | |
TARMIC, NCT02805725: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide |
|
|
| Completed | 1/2 | 50 | Europe | Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide, Phase 2: Cyclophosphamide | Institut Bergonié, PharmaMar | Soft-tissue Sarcomas | 04/20 | 12/21 | | |
SAINT, NCT03138161: Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 45 | US | Trabectedin, Yondelis, Ipilimumab, Yervoy, Nivolumab, Opdivo | Sarcoma Oncology Research Center, LLC, Bristol-Myers Squibb | Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma | 12/24 | 03/25 | | |
SARC037, NCT04067115: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients |
|
|
| Active, not recruiting | 1/2 | 48 | US | Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging | Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI) | Ewing Sarcoma | 06/24 | 06/24 | | |
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. |
|
|
| Completed | 1 | 40 | Europe | Combination of trabectedin with durvalumab | Institut Bergonié, AstraZeneca, PharmaMar | Ovarian Carcinoma, Soft Tissue Sarcoma | 11/20 | 01/22 | | |
|
NCT01427582: YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access |
|
|
| No Longer Available | N/A | | US | Trabectedin, YONDELIS | University of Texas Southwestern Medical Center, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Soft Tissue Sarcoma | | | | |
NCT00210665: A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment |
|
|
| No Longer Available | N/A | | US, Canada, RoW | Trabectedin | Janssen Research & Development, LLC | Sarcoma | | | | |
PROTraSarc, NCT06050434: Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients |
|
|
| Recruiting | N/A | 100 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, PharmaMar | Soft Tissue Sarcoma | 05/25 | 12/25 | | |